Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...

The drug candidate is administered orally in the form of a film-coated tablet ... in the UK and around the world. AstraZeneca submitted a compliant application for the clinical study to the ...

The global active pharmaceutical ingredients market size was worth USD 239.18 billion in 2024 and is expected to reach around USD 368.49 billion by 2033, with a noteworthy CAGR of 5.64% from 2023 to ...

LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology firm focused on neurogenetic medicines with a market capitalization of $290 million, announced today it is reassessing its ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

A class action lawsuit was filed against AstraZeneca Plc (AZN) by Levi & Korsinsky on December 23, 2024. The plaintiffs ...

Investors with a lot of money to spend have taken a bullish stance on AstraZeneca AZN. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca is a company with a turbulent history ... and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies ...

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is ...